Biotech Values

[DewDiligence]

Biolex, private co., files for bankruptcy.

This became a foregone conclusion when Biolex sold the Locteron HCV program—as well as the LEX production platform on which it was based—at a firesale price two months ago (#msg-75396129).

Locteron, a form of interferon manufactured in transgenic plants, was once considered among the most promising HCV programs from any company; however, the commercial relevance of the program faded along with the emphasis on developing all-oral regimens for HCV.